# US 2025/0144099 A1 · Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144099 A1
- Document ID: US20250144099A1
- Status: Published application
- Kind: A1
- Application number: 18/690,228
- Filed: 2022-09-08
- Published: 2025-05-08
- Earliest claimed: 2021-09-08
- Applicants: Memorial Sloan-Kettering Cancer Center; Dana-Farber Cancer Institute; Stevens Institute of Technology; Memorial Hospital for Cancer and Allied Diseases; Sloan-Kettering Institute for Cancer Research
- Inventors: Sarat Chandarlapaty; Qing Li; Nathanael Gray; Baishan Jiang; Abhishek Sharma; Aiswarya Mini
- Web page: https://patentgrep.com/patent/US20250144099A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure relates to compounds according to Formula (I), Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, compositions including such compounds, and methods useful for treating, preventing, and/or ameliorating a CDK4 and/or CDK6-mediated disorder, disease, or condition (e.g., cancer such as breast cancer) in a subject.

## Claims

### Claim 1

A compound according to Formula (I)
or a pharmaceutically acceptable salt and/or solvate thereof, wherein
L is selected from the group consisting of
T is selected from the group consisting of
ring A is a 4- to 7-membered N-containing heterocycloalkylene optionally substituted with one or more groups selected from halogen and C1-C3 alkyl;
Cy is a C4-C6 cycloalkylene optionally substituted with one or more groups selected from halogen and C1-C3 alkyl;
R and R3 are each independently H or C1-C3 alkyl;
R1 and R2 are taken together to form an oxo (=O) group;
R4 is H, halo, C1-C4 alkyl, or C3-C6 cycloalkyl;
L1 is a C1-C6 alkylene;
* is the linkage site to the nitrogen atom of the piperazine moiety; and
# is the linkage site to the T group.

### Claim 2 (depends on 1)

The compound of claim 1, having a structure according to Formula (II)
or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 3 (depends on 2)

The compound claim 2, wherein L is

### Claim 4 (depends on 2)

The compound claim 2, wherein L is

### Claim 5 (depends on 2)

The compound of claim 2, having a structure according to Formula (IIa)
or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein ring A is selected from the group consisting of
wherein
R11 and R12 are each independently H or halogen;
R13 and R14 are each independently H, halogen, or C1-C3 alkyl;
** is the linkage site to the L1 group; and
# is the linkage site to the T group.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R13 is H, F, or Me.

### Claim 8 (depends on 6)

The compound of claim 6, wherein R14 is H or F.

### Claim 9 (depends on 6)

The compound of claim 6, wherein R11 and R12 are each independently H or F.

### Claim 10 (depends on 5)

The compound of claim 5, wherein L1 is a methylene.

### Claim 11 (depends on 2)

The compound of claim 2, wherein L is selected from the group consisting of
wherein
* is the linkage site to the nitrogen atom of the piperazine moiety; and
# is the linkage site to the T group.

### Claim 12 (depends on 2)

The compound of claim 2, wherein
R3 is H.

### Claim 13 (depends on 1)

The compound of claim 1, having a structure according to Formula (III)
or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising
a compound according to claim 1 or a pharmaceutically acceptable salt and/or solvate thereof; and
a pharmaceutically acceptable carrier.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A method for inducing degradation of CDK4 and/or CDK6 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the method induces degradation of both CDK4 and CDK6.

### Claim 19 (depends on 1)

A method for treating a CDK4 and/or CDK6-mediated disorder, disease, or condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the disorder, disease, or condition is cancer.

### Claim at position 21

-22. (canceled)

### Claim 23 (depends on 1)

A method for treating breast cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt and/or solvate thereof.
